Nicole Mayer Hamblett, PhD

Nicole Mayer Hamblett, PhD

Cystic Fibrosis Research

Academic Title: Research Associate Professor

Research Center: Center for Clinical and Translational Research

Nicole Mayer Hamblett, PhD, is an associate professor in the Division of Pulmonary Medicine at Seattle Children's Hospital and in the Departments of Pediatrics and Biostatistics at the University of Washington . Dr. Hamblett is a Co-Director of the Cystic Fibrosis Therapeutics Development Network Coordinating Center and the Seattle Children's Core for Biomedical Research. Her research interests include the design and analysis of clinical trials, with emphasis in the pediatric and orphan disease setting. She is involved in the development of new clinical outcome measures for cystic fibrosis and, in particular, the validation of biomarkers to enable early evaluation of new therapies. Dr. Hamblett also provides statistical training to clinical researchers and scientists, with applications to both the preclinical and clinical fields.


Research Focus Area

Translational Research


  • Simon TD, Whitlock KB, Riva-Cambrin J, Kestle JR, Rosenfeld M, Dean JM, Holubkov R, Langley M, Hamblett NM
    Revision surgeries are associated with significant increased risk of subsequent cerebrospinal fluid shunt infection.
    22333701 The Pediatric infectious disease journal , 2012 June : 31(6)551-6 PMCID: PMC3356497
  • Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, for the EPIC Investigators
    Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
    21830317 Pediatric pulmonology , 2012 Feb. : 125-134 PMCID: PMC3214247
  • Simon TD, Whitlock KB, Riva-Cambrin J, Kestle JR, Rosenfeld M, Dean JM, Holubkov R, Langley M, Mayer-Hamblett N
    Association of intraventricular hemorrhage secondary to prematurity with cerebrospinal fluid shunt surgery in the first year following initial shunt placement.
    22208322 Journal of Neurosurgery. Pediatrics , 2012 Jan. : 54-63 PMCID: PMC3254255
  • Quon BS, Mayer-Hamblett N, Aitken ML, Goss CH
    Risk of Post Lung Transplant Renal Dysfunction in Adults with Cystic Fibrosis.
    22222189 Chest , 2012 Jan.
  • Quon BS, Mayer-Hamblett N, Aitken ML, Smyth AR, Goss CH
    Risk factors for chronic kidney disease in adults with cystic fibrosis.
    21799076 American journal of respiratory and critical care medicine , 2011 Nov. : 1147-52 PMCID: PMC3262023
  • Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW, Early Pseudomonas Infection Control (EPIC) Investigators
    Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
    21893650 Archives of pediatrics & adolescent medicine , 2011 Sept. : 847-56
  • Tuan TJ, Thorell EA, Hamblett NM, Kestle JR, Rosenfeld M, Simon TD
    Treatment and microbiology of repeated cerebrospinal fluid shunt infections in children.
    21852762 The Pediatric infectious disease journal , 2011 Sept. : 731-5 PMCID: PMC3160174
  • Green N, Burns JL, Mayer-Hamblett N, Kloster M, Lands LC, Anstead M, Ratjen F, Saiman L
    Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis.
    21543567 Journal of clinical microbiology , 2011 July : 2772-3 PMCID: PMC3147847
  • Rogers GB, Hoffman LR, Johnson MW, Mayer-Hamblett N, Schwarze J, Carroll MP, Bruce KD
    Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.
    21405970 Expert review of molecular diagnostics , 2011 Mar. : 197-206 PMCID: PMC3148893
  • Nicole Hamblett, PhD, Saiman L, Mayer-Hamblett N, Anstead M, Lands L, Kloster M, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F for the AZ0004 Study
    Open-label, Follow-On Study to Assess Continued Efficacy and Safety of Azithromycin in Children and Adolescents with CF Uninfected with Pseudomonas aeruginosa.
    Pediatric Pulmonology (In press) , 2011
  • Solomon GM, Konstan MW, Wilschanski M, Billings J, Sermet-Gaudelus I, Accurso F, Vermeulen F, Levin E, Hathorne H, Reeves G, Sabbatini G, Hill A, Mayer-Hamblett N, Ashlock M, Clancy JP, Rowe SM
    An international randomized multicenter comparison of nasal potential difference techniques.
    20472865 Chest , 2010 Oct. : 919-28 PMCID: PMC2951758
  • Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F, AZ0004 Azithromycin Study Group
    Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
    20442386 JAMA : the journal of the American Medical Association , 2010 May : 1707-15
  • Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, EPIC Study Group
    Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
    19470318 Contemporary clinical trials , 2009 May : 256-68 PMCID: PMC2783320
  • Sanders DB, Rosenfeld M, Mayer-Hamblett N, Stamey D, Redding GJ
    Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations.
    18846562 Pediatric pulmonology , 2008 Nov. : 1142-6
  • Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, Konstan MW, Wagener JS, Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (ESCF)
    Shifting patterns of inhaled antibiotic use in cystic fibrosis.
    18668689 Pediatric pulmonology , 2008 Sept. : 874-81
  • Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW
    Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
    17534969 Pediatric pulmonology , 2007 July : 610-23
  • Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, Mayer-Hamblett N, Ramsey B
    No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
    17347447 American journal of respiratory cell and molecular biology , 2007 July : 57-66 PMCID: PMC1899350
  • Nguyen D, Emond MJ, Mayer-Hamblett N, Saiman L, Marshall BC, Burns JL
    Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
    17469154 Pediatric pulmonology , 2007 June : 533-41
  • Goss CH, Mayer-Hamblett N, Kronmal RA, Williams J, Ramsey BW
    Laboratory parameter profiles among patients with cystic fibrosis.
    16829217 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2007 Apr, : 117-23
  • Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW
    Association between pulmonary function and sputum biomarkers in cystic fibrosis.
    17234902 American journal of respiratory and critical care medicine , 2007 Apr, : 822-8 PMCID: PMC2720115
  • Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC, Macrolide Study Group
    Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
    16040785 American journal of respiratory and critical care medicine , 2005 Oct. : 1008-12
  • Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K
    Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
    15573395 Pediatric pulmonology , 2005 Mar. : 209-18
  • Mayer-Hamblett N, Kronmal RA
    Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting.
    15837448 Contemporary clinical trials , 2005 Feb. : 2-16
  • Beckmann C, Brittnacher M, Ernst R, Mayer-Hamblett N, Miller SI, Burns JL
    Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.
    15618183 Infection and immunity , 2005 Jan. : 444-52 PMCID: PMC538986
  • Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW
    Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.
    15516471 Thorax , 2004 Nov. : 955-9 PMCID: PMC1746887
  • Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE
    Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.
    14769732 Chest , 2004 Feb. : 509-21
  • Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML
    Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.
    12969869 American journal of respiratory and critical care medicine , 2003 Dec. : 1471-5
  • Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd, Macrolide Study Group
    Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    14519709 JAMA : the journal of the American Medical Association , 2003 Oct. : 1749-56
  • Piedra PA, Cron SG, Jewell A, Hamblett N, McBride R, Palacio MA, Ginsberg R, Oermann CM, Hiatt PW, Purified Fusion Protein Vaccine Study Group
    Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis.
    12744878 Vaccine , 2003 June : 2448-60
  • Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL
    Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
    12740266 Chest , 2003 May : 1495-502
  • Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B
    Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    12480612 American journal of respiratory and critical care medicine , 2003 Mar. : 841-9
  • Goss CH, Mayer-Hamblett N, Kronmal RA, Ramsey BW
    The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases.
    12458158 Advanced drug delivery reviews , 2002 Dec. : 1505-28
  • Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML
    Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
    12406843 American journal of respiratory and critical care medicine , 2002 Dec. : 1550-5
  • Cieri MV, Mayer-Hamblett N, Griffith A, Burns JL
    Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection.
    11854186 Infection and immunity , 2002 Mar. : 1081-6 PMCID: PMC127769
  • Noone PG, Hamblett N, Accurso F, Aitken ML, Boyle M, Dovey M, Gibson R, Johnson C, Kellerman D, Konstan MW, Milgram L, Mundahl J, Retsch-Bogort G, Rodman D, Williams-Warren J, Wilmott RW, Zeitlin P, Ramsey B, Cystic Fibrosis Therapeutics Development Research Group
    Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.
    11477729 Pediatric pulmonology , 2001 Aug. : 122-8
  • Mayer-Hamblett N, Self S
    A regression modeling approach for describing patterns of HIV genetic variation.
    11414569 Biometrics , 2001 June : 449-60
  • Nicole Hamblett, PhD, Simon TD, Whitlock KB, Riva-Cambrin J, Kestle JRW, Rosenfeld M, Dean JM, Holubkov R, Langley M, Mayer-Hamblett N
    Revision surgeries are associated with significant increased risk of subsequent cerebrospinal fluid shunt infection
    Pediatric Disease Journal (In press)

Research Funding

Grant Title Grantor Amount Award Date
Rates of Hemoptysis Among Individuals with Cystic Fibrosis Enrolled in Clinical Trials Pharmaxis Ltd. Feb. 1, 2014
Long Term Outcomes After Eradication of Pseudomonas Aeruginosa Among Children Enrolled in EPIC Clinical Novartis Pharmaceuticals Corp. Dec. 15, 2013
Optimizing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE NIH/NHLBI Sept. 15, 2013
G551D Observational Study Expanded to Include Additional Genotypes and Extended for Long Term Followup Cystic Fibrosis Foundation Therapeutics Sept. 1, 2013
A Multicenter Study of the Effects of AquADEKs-2 on Markers of Inflammation and Oxidative Stress in CF Cystic Fibrosis Foundation Therapeutics Aug. 1, 2012
Pseudomonas Aeruginosa Adaptation During Early CF Airway Infection and Treatment NIH Sept. 11, 2009
Institute of Translational Health Sciences NIH/NCATS Sept. 17, 2007